Multiple types of oncolytic viruses are currently under investigation in clinical trials. To optimize therapeutic outcomes it is believed that the plethora of different tumor types will require a diversity of different virus types. Sendai virus (SeV), a murine parainfluenza virus, displays a broad host range, enters cells within minutes and already has been applied safely as a gene transfer vector in gene therapy patients. However, SeV spreading naturally is abrogated in human cells due to a lack of virus activating proteases. To enable oncolytic applications of SeV we here engineered a set of novel recombinant vectors by a two-step approach: (i) introduction of an ubiquitously recognized cleavage-motive into SeV fusion protein now enabling continuous spreading in human tissues, and (ii) profound attenuation of these rSeV by the knockout of viral immune modulating accessory proteins. When employing human hepatoma cell lines, newly generated SeV variants now reached high titers and induced a profound tumor cell lysis. In contrast, virus release from untransformed human fibroblasts or primary human hepatocytes was found to be reduced by about three log steps in a time course experiment which enables the cumulation of kinetic differences of the distinct phases of viral replication such as primary target cell infection, target cell replication, and progeny virus particle release. In a hepatoma xenograft animal model we found a tumor-specific spreading of our novel recombinant SeV vectors without evidence of biodistribution into non-malignant tissues. In conclusion, we successfully developed novel tumor-selective oncolytic rSeV vectors, constituting a new tool for virotherapy of solid tumors being ready for further preclinical and clinical development to address distinct tumor types.
References
[1]
Hawkins LK, Lemoine NR, Kirn D (2002) Oncolytic biotherapy: a novel therapeutic platform. Lancet Oncol 3: 17–26. doi: 10.1016/s1470-2045(01)00618-0
[2]
Kelly E, Russell SJ (2007) History of oncolytic viruses: genesis to genetic engineering. Mol Ther 15: 651–659. doi: 10.1038/sj.mt.6300108
[3]
Bourke MG, Salwa S, Harrington KJ, Kucharczyk MJ, Forde PF, et al. (2011) The emerging role of viruses in the treatment of solid tumours. Cancer Treat Rev 37: 618–632. doi: 10.1016/j.ctrv.2010.12.003
Cattaneo R, Miest T, Shashkova EV, Barry MA (2008) Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 6: 529–540. doi: 10.1038/nrmicro1927
[6]
Linge C, Gewert D, Rossmann C, Bishop JA, Crowe JS (1995) Interferon system defects in human malignant melanoma. Cancer Res 55: 4099–4104.
[7]
Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, et al. (2003) VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4: 263–275. doi: 10.1016/s1535-6108(03)00241-1
[8]
Naik S, Russell SJ (2009) Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin Biol Ther 9: 1163–1176. doi: 10.1517/14712590903170653
[9]
Persano L, Moserle L, Esposito G, Bronte V, Barbieri V, et al. (2009) Interferon-alpha counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer. Carcinogenesis 30: 851–860. doi: 10.1093/carcin/bgp052
[10]
Patel MR, Kratzke RA (2013) Oncolytic virus therapy for cancer: the first wave of translational clinical trials. Transl Res 161: 355–364. doi: 10.1016/j.trsl.2012.12.010
[11]
Bitzer M, Armeanu S, Lauer UM, Neubert WJ (2003) Sendai virus vectors as an emerging negative-strand RNA viral vector system. J Gene Med 5: 543–553. doi: 10.1002/jgm.426
[12]
Blechacz B, Splinter PL, Greiner S, Myers R, Peng KW, et al. (2006) Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology 44: 1465–1477. doi: 10.1002/hep.21437
[13]
Lech PJ, Russell SJ (2010) Use of attenuated paramyxoviruses for cancer therapy. Expert Rev Vaccines 9: 1275–1302. doi: 10.1586/erv.10.124
[14]
Laurie SA, Bell JC, Atkins HL, Roach J, Bamat MK, et al. (2006) A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin Cancer Res 12: 2555–2562. doi: 10.1158/1078-0432.ccr-05-2038
[15]
Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, et al.. (2010) Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer. Cancer Res.
[16]
Slobod KS, Shenep JL, Lujan-Zilbermann J, Allison K, Brown B, et al. (2004) Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine 22: 3182–3186. doi: 10.1016/j.vaccine.2004.01.053
[17]
Yonemitsu Y, Matsumoto T, Itoh H, Okazaki J, Uchiyama M, et al. (2013) DVC1-0101 to Treat Peripheral Arterial Disease: A Phase I/IIa Open-label Dose-escalation Clinical Trial. Mol Ther 21: 707–714. doi: 10.1038/mt.2012.279
[18]
Markwell MA, Fredman P, Svennerholm L (1984) Specific gangliosides are receptors for Sendai virus. Proteins in lipid samples can mask positive biological effects. Adv Exp Med Biol 174: 369–379.
[19]
Markwell MA, Paulson JC (1980) Sendai virus utilizes specific sialyloligosaccharides as host cell receptor determinants. Proc Natl Acad Sci U S A 77: 5693–5697. doi: 10.1073/pnas.77.10.5693
[20]
Markwell MA, Svennerholm L, Paulson JC (1981) Specific gangliosides function as host cell receptors for Sendai virus. Proc Natl Acad Sci U S A 78: 5406–5410. doi: 10.1073/pnas.78.9.5406
[21]
Villar E, Barroso IM (2006) Role of sialic acid-containing molecules in paramyxovirus entry into the host cell: a minireview. Glycoconj J 23: 5–17. doi: 10.1007/s10719-006-5433-0
[22]
Kido H, Yokogoshi Y, Sakai K, Tashiro M, Kishino Y, et al. (1992) Isolation and characterization of a novel trypsin-like protease found in rat bronchiolar epithelial Clara cells. A possible activator of the viral fusion glycoprotein. J Biol Chem 267: 13573–13579.
[23]
Kinoh H, Inoue M, Washizawa K, Yamamoto T, Fujikawa S, et al. (2004) Generation of a recombinant Sendai virus that is selectively activated and lyses human tumor cells expressing matrix metalloproteinases. Gene Ther 11: 1137–1145. doi: 10.1038/sj.gt.3302272
[24]
Kinoh H, Inoue M, Komaru A, Ueda Y, Hasegawa M, et al. (2009) Generation of optimized and urokinase-targeted oncolytic Sendai virus vectors applicable for various human malignancies. Gene Ther 16: 392–403. doi: 10.1038/gt.2008.167
[25]
Hasegawa Y, Kinoh H, Iwadate Y, Onimaru M, Ueda Y, et al. (2010) Urokinase-targeted fusion by oncolytic Sendai virus eradicates orthotopic glioblastomas by pronounced synergy with interferon-beta gene. Mol Ther 18: 1778–1786. doi: 10.1038/mt.2010.138
[26]
Garcin D, Latorre P, Kolakofsky D (1999) Sendai virus C proteins counteract the interferon-mediated induction of an antiviral state. J Virol 73: 6559–6565.
[27]
Gotoh B, Takeuchi K, Komatsu T, Yokoo J, Kimura Y, et al. (1999) Knockout of the Sendai virus C gene eliminates the viral ability to prevent the interferon-alpha/beta-mediated responses. FEBS Lett 459: 205–210. doi: 10.1016/s0014-5793(99)01241-7
[28]
Komatsu T, Takeuchi K, Yokoo J, Gotoh B (2004) C and V proteins of Sendai virus target signaling pathways leading to IRF-3 activation for the negative regulation of interferon-beta production. Virology 325: 137–148. doi: 10.1016/j.virol.2004.04.025
[29]
Strahle L, Marq JB, Brini A, Hausmann S, Kolakofsky D, et al. (2007) Activation of the beta interferon promoter by unnatural Sendai virus infection requires RIG-I and is inhibited by viral C proteins. J Virol 81: 12227–12237. doi: 10.1128/jvi.01300-07
[30]
Takeuchi K, Komatsu T, Yokoo J, Kato A, Shioda T, et al. (2001) Sendai virus C protein physically associates with Stat1. Genes Cells 6: 545–557. doi: 10.1046/j.1365-2443.2001.00442.x
[31]
Wiegand MA, Bossow S, Schlecht S, Neubert WJ (2007) De novo synthesis of N and P proteins as a key step in Sendai virus gene expression. J Virol 81: 13835–13844. doi: 10.1128/jvi.00914-07
[32]
K？rber G (1931) Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. [A contribution to the collective treatment of a pharmacological experimental series.]. Archiv für experimentelle Pathologie und Pharmakologie 162: 480–483. doi: 10.1007/bf01863914
[33]
Armeanu S, Krusch M, Baltz KM, Weiss TS, Smirnow I, et al. (2008) Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma. Clin Cancer Res 14: 3520–3528. doi: 10.1158/1078-0432.ccr-07-4744
[34]
Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, et al. (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107–1112. doi: 10.1093/jnci/82.13.1107
[35]
Koyama S, Ishii KJ, Coban C, Akira S (2008) Innate immune response to viral infection. Cytokine 43: 336–341. doi: 10.1016/j.cyto.2008.07.009
[36]
Fontana JM, Bankamp B, Rota PA (2008) Inhibition of interferon induction and signaling by paramyxoviruses. Immunol Rev 225: 46–67. doi: 10.1111/j.1600-065x.2008.00669.x
[37]
Kato A, Cortese-Grogan C, Moyer SA, Sugahara F, Sakaguchi T, et al. (2004) Characterization of the amino acid residues of sendai virus C protein that are critically involved in its interferon antagonism and RNA synthesis down-regulation. J Virol 78: 7443–7454. doi: 10.1128/jvi.78.14.7443-7454.2004
[38]
Kurotani A, Kiyotani K, Kato A, Shioda T, Sakai Y, et al. (1998) Sendai virus C proteins are categorically nonessential gene products but silencing their expression severely impairs viral replication and pathogenesis. Genes Cells 3: 111–124. doi: 10.1046/j.1365-2443.1998.00170.x
[39]
Yoshida A, Sakaguchi T, Irie T (2012) Passage of a Sendai virus recombinant in embryonated chicken eggs leads to markedly rapid accumulation of U-to-C transitions in a limited region of the viral genome. PLoS One 7: e49968. doi: 10.1371/journal.pone.0049968
[40]
Latorre P, Cadd T, Itoh M, Curran J, Kolakofsky D (1998) The various Sendai virus C proteins are not functionally equivalent and exert both positive and negative effects on viral RNA accumulation during the course of infection. J Virol 72: 5984–5993.
[41]
Bitzer M, Lauer UM (2003) [Oncolytic viruses for genetic therapy of gastrointestinal tumors]. Z Gastroenterol 41: 667–674.
[42]
Keskinen P, Nyqvist M, Sareneva T, Pirhonen J, Melen K, et al. (1999) Impaired antiviral response in human hepatoma cells. Virology 263: 364–375. doi: 10.1006/viro.1999.9983
[43]
Marozin S, Altomonte J, Stadler F, Thasler WE, Schmid RM, et al. (2008) Inhibition of the IFN-beta response in hepatocellular carcinoma by alternative spliced isoform of IFN regulatory factor-3. Mol Ther 16: 1789–1797. doi: 10.1038/mt.2008.201
[44]
Li K, Chen Z, Kato N, Gale M Jr, Lemon SM (2005) Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes. J Biol Chem 280: 16739–16747. doi: 10.1074/jbc.m414139200
[45]
Bitzer M, Prinz F, Bauer M, Spiegel M, Neubert WJ, et al. (1999) Sendai virus infection induces apoptosis through activation of caspase-8 (FLICE) and caspase-3 (CPP32). J Virol 73: 702–708.
[46]
Bitzer M, Ungerechts G, Bossow S, Graepler F, Sedlmeier R, et al. (2003) Negative-strand RNA viral vectors: intravenous application of Sendai virus vectors for the systemic delivery of therapeutic genes. Mol Ther 7: 210–217. doi: 10.1016/s1525-0016(02)00052-7
[47]
Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, et al. (2011) Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477: 99–102. doi: 10.1038/nature10358
[48]
Haddad D, Zanzonico PB, Carlin S, Chen CH, Chen NG, et al. (2012) A vaccinia virus encoding the human sodium iodide symporter facilitates long-term image monitoring of virotherapy and targeted radiotherapy of pancreatic cancer. J Nucl Med 53: 1933–1942. doi: 10.2967/jnumed.112.105056
[49]
Stritzker J, Kirscher L, Scadeng M, Deliolanis NC, Morscher S, et al. (2013) Vaccinia virus-mediated melanin production allows MR and optoacoustic deep tissue imaging and laser-induced thermotherapy of cancer. Proc Natl Acad Sci U S A 110: 3316–3320. doi: 10.1073/pnas.1216916110
[50]
Lemken ML, Graepler F, Wolf C, Wybranietz WA, Smirnow I, et al. (2007) Fusion of HSV-1 VP22 to a bifunctional chimeric SuperCD suicide gene compensates for low suicide gene transduction efficiencies. Int J Oncol 30: 1153–1161. doi: 10.3892/ijo.30.5.1153
[51]
Berchtold S, Lampe J, Weiland T, Smirnow I, Schleicher S, et al. (2013) Innate immune defense defines susceptibility of sarcoma cells to measles vaccine virus-based oncolysis. J Virol 87: 3484–3501. doi: 10.1128/jvi.02106-12
[52]
Park BH, Hwang T, Liu TC, Sze DY, Kim JS, et al. (2008) Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 9: 533–542. doi: 10.1016/s1470-2045(08)70107-4
